Clinical ResearchPediatric CardiologyEfficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia
Key Words
Abbreviations and Acronyms
Cited by (0)
This study was funded by AstraZeneca. Dr. Gagné has received research support, consultant honoraria, and lecture fees from AstraZeneca, Genzyme Isis, Takeda, Merck, Schering-Plough, and Pfizer. Dr. Langslet has received travel funding or lecture fees from AstraZeneca, Bristol-Myers Squibb, Genzyme, Merck Sharp and Dohme, Pfizer, and Schering-Plough. Dr. McCrindle has received consulting fees from Roche, Abbott, and Eli Lilly. Dr. Hsia is employed by and owns stock in AstraZeneca. Dr. Kastelein has received grant support from AstraZeneca, Pfizer, Roche, Novartis, Merck, Merck–Schering-Plough, Isis, Genzyme, and Sanofi-Aventis; lecture fees from AstraZeneca, GlaxoSmithKline, Pfizer, Novartis, Merck–Schering-Plough, Roche, Isis, and Boehringer Ingelheim; and consulting fees from AstraZeneca, Abbott, Pfizer, Isis, Genzyme, Roche, Novartis, Merck, Merck–Schering-Plough, and Sanofi-Aventis. Dr. Stein has received grants for trials of lipid-modifying agents, consulting fees, and honoraria for professional input regarding lipid-altering agents, and/or has delivered lectures for the American Association for Clinical Chemistry, Abbott, AstraZeneca, the Food and Drug Administration, F. Hoffmann-La Roche, GlaxoSmithKline, Isis, Merck & Co., National Lipid Association, Novartis, Reliant, Sankyo, Sanofi-Aventis, Schering-Plough, Takeda, and Wyeth. The initial paper was developed by the primary authors (Drs. Avis and Stein) and additional editorial support during the subsequent preparation of this paper was provided and funded by AstraZeneca.